Trials / Terminated
TerminatedNCT00757757
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCS110 | Anti-M-CSF antibody |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-09-23
- Last updated
- 2020-12-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00757757. Inclusion in this directory is not an endorsement.